James Paxton

List of Publications by Year in Descending Order

140 papers	3,985 citations	33 h-index	56 g-index
140 ext. papers	4,196 ext. citations	4.3 avg, IF	5.15 L-index

#	Paper	IF	Citations
140	Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine. *Pharmaceutical Research*, **2021**, 38, 1209-1219	4.5	5
139	Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells. *European Journal of Pharmacology*, **2017**, 803, 167-173	5.3	7
138	The effects of dietary and herbal phytochemicals on drug transporters. *Advanced Drug Delivery Reviews*, **2017**, 116, 45-62	18.5	33
137	Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. *Pharmaceutical Research*, **2016**, 33, 1628-37	4.5	21
136	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. *PLoS ONE*, **2015**, 10, e0130727	3.7	26
135	Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance. *Biochemical Pharmacology*, **2015**, 93, 305-17	6	27
134	Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. *Pharmaceutical Research*, **2015**, 32, 2428-38	4.5	44
133	Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent. *Cancer Chemotherapy and Pharmacology*, **2014**, 74, 25-35	3.5	6
132	Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2). *European Journal of Pharmacology*, **2014**, 723, 346-52	5.3	34
131	Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells. *Pharmaceutical Research*, **2014**, 31, 2583-92	4.5	31
130	Development of a gradient high performance liquid chromatography assay for simultaneous analysis of hydrophilic gemcitabine and lipophilic curcumin using a central composite design and its application in liposome development. *Journal of Pharmaceutical and Biomedical Analysis*, **2014**, 98, 371-8	3.5	19
129	Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2). *Molecular Nutrition and Food Research*, **2014**, 58, 2099-110	5.9	25
128	Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent. *Cancer Chemotherapy and Pharmacology*, **2013**, 72, 1013-22	3.5	4
127	The effects of flavonoids on the ABC transporters: consequences for the pharmacokinetics of substrate drugs. *Expert Opinion on Drug Metabolism and Toxicology*, **2013**, 9, 267-85	5.5	32
126	Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). *Food Chemistry*, **2013**, 138, 2267-74	8.5	74
125	A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development. *Journal of Pharmaceutical and Biomedical Analysis*, **2012**, 63, 9-16	3.5	7
124	The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics. *Current Drug Metabolism*, **2012**, 13, 624-39	3.5	32

123	Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics. *Cancer Chemotherapy and Pharmacology*, **2012**, 70, 151-60	3.5	8
122	Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. *Cancer Chemotherapy and Pharmacology*, **2011**, 68, 603-10	3.5	41
121	Farewell Peter Nigel Black FRACP. *Respirology*, **2010**, 15, 383-384	3.6	1
120	Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. *Drug Metabolism Reviews*, **2010**, 42, 590-611	7	38
119	Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion. *Journal of Drug Targeting*, **2010**, 18, 125-33	5.4	38
118	Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. *Cancer Chemotherapy and Pharmacology*, **2010**, 65, 1145-52	3.5	8
117	Improving the oral bioavailability of beneficial polyphenols through designed synergies. *Genes and Nutrition*, **2010**, 5, 75-87	4.3	118
116	Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs. *Investigational New Drugs*, **2009**, 27, 280-4	4.3	10
115	Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. *International Journal of Pharmaceutics*, **2009**, 367, 179-86	6.5	89
114	Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049). *Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences*,	3.2	7
113	Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. *Journal of Pharmaceutical and Biomedical Analysis*, **2008**, 46, 386-90	3.5	5
112	Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. *International Journal of Pharmaceutics*, **2008**, 360, 115-21	6.5	56
111	The xenobiotic transporter ABCG2 plays a novel role in differentiation of trophoblast-like BeWo cells. *Placenta*, **2007**, 28 Suppl A, S116-20	3.4	37
110	Expression, localisation and activity of ATP binding cassette (ABC) family of drug transporters in human amnion membranes. *Placenta*, **2007**, 28, 868-77	3.4	43
109	Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial. *Cancer Chemotherapy and Pharmacology*, **2007**, 59, 681-7	3.5	18
108	The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. *FASEB Journal*, **2007**, 21, 3592-605	0.9	84
107	Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. *Drug Metabolism and Disposition*, **2007**, 35, 595-601	4	135
106	ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2006**, 290, R1357-65	3.2	120

105	Active transport across the human placenta: impact on drug efficacy and toxicity. *Expert Opinion on Drug Metabolism and Toxicology*, **2006**, 2, 51-69	5.5	65
104	Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study. *Clinical and Experimental Pharmacology and Physiology*, **2005**, 32, 633-9	3	6
103	Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. *European Journal of Pharmaceutical Sciences*, **2005**, 24, 513-24	5.1	28
102	Transport of thalidomide by the human intestinal caco-2 monolayers. *European Journal of Drug Metabolism and Pharmacokinetics*, **2005**, 30, 49-61	2.7	13
101	Prediction of herb-drug metabolic interactions: a simulation study. *Phytotherapy Research*, **2005**, 19, 464-71	6.7	17
100	Human placental glucuronidation and transport of 3′-azido-3′-deoxythymidine and uridine diphosphate glucuronic acid. *Drug Metabolism and Disposition*, **2004**, 32, 813-20	4	30
99	Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2004**, 809, 87-97	3.2	10
98	Drug transfer and metabolism by the human placenta. *Clinical Pharmacokinetics*, **2004**, 43, 487-514	6.2	406
97	Predicting pharmacokinetic herb-drug interactions. *Drug Metabolism and Drug Interactions*, **2004**, 20, 143-58		26
96	Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. *Biochemical Pharmacology*, **2003**, 65, 109-20	6	12
95	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. *Biochemical Pharmacology*, **2003**, 65, 1853-65	6	5
94	3′-azido-3′-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta. *Toxicology and Applied Pharmacology*, **2003**, 192, 164-73	4.6	32
93	Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2003**, 785, 165-73	3.2	19
92	Interactions of herbs with cytochrome P450. *Drug Metabolism Reviews*, **2003**, 35, 35-98	7	320
91	Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species. *Journal of Pharmacy and Pharmacology*, **2002**, 54, 997-1003	4.8	2
90	UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. *Biochemical Pharmacology*, **2002**, 63, 409-19	6	91
89	6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3. *European Journal of Drug Metabolism and Pharmacokinetics*, **2002**, 27, 179-83	2.7	12
88	Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). *Cancer Chemotherapy and Pharmacology*, **2002**, 49, 126-32	2.5	8

87	Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. *Cancer Chemotherapy and Pharmacology*, **2002**, 50, 186-92	3.5	18
86	Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2002**, 776, 231-6	3.2	2
85	High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2002**, 767, 19-26	3.2	2
84	5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. *Investigational New Drugs*, **2002**, 20, 281-95	4.3	34
83	Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. *Xenobiotica*, **2002**, 32, 87-107	2	21
82	Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. *Human Reproduction*, **2002**, 17, 2564-72	5.7	88
81	Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. *Drug Metabolism Reviews*, **2002**, 34, 751-90	7	17
80	Thalidomide in cancer treatment: a potential role in the elderly?. *Drugs and Aging*, **2002**, 19, 85-100	4.7	15
79	Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. *Journal of Pharmacy and Pharmacology*, **2001**, 53, 463-71	4.8	18
78	In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. *Cancer Chemotherapy and Pharmacology*, **2001**, 47, 319-26	3.5	18
77	A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide. *Cancer Chemotherapy and Pharmacology*, **2001**, 47, 541-4	3.5	9
76	Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography. *Biomedical Applications*, **2001**, 757, 343-8		8
75	Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection. *Biomedical Applications*, **2001** 757, 359-63		4
74	Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. *British Journal of Clinical Pharmacology*, **2001**, 52, 129-36	3.8	12
73	Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. *Xenobiotica*, **2001**, 31, 277-93	2	30
72	Inter-species variation in the metabolism and inhibition of N-[(2-dimethylamino)ethyl]acridine-4-carboxamide (DACA) by aldehyde oxidase. *Biochemical Pharmacology*, **2000**, 59, 161-5	6	39
71	Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. *Cancer Chemotherapy and Pharmacology*, **2000**, 46, 135-41	3.5	29
70	A highly sensitive fluorescent microplate method for the determination of UDP-glucuronosyl transferase activity in tissues and placental cell lines. *Drug Metabolism and Disposition*, **2000**, 28, 1184-6	4	55

69	Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. *Drug Metabolism and Disposition*, **2000**, 28, 1449-56	4	42
68	Determinaton of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection. *Biomedical Applications*, **1999**, 734, 129-36		14
67	Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. *Cancer Chemotherapy and Pharmacology*, **1999**, 43, 323-30	3.5	40
66	Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial. *Cancer Chemotherapy and Pharmacology*, **1999**, 44, 45-50	3.5	20
65	Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial. *Cancer Chemotherapy and Pharmacology*, **1999**, 44, 51-8	3.5	26
64	The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anti-cancer drugs. *Clinical and Experimental Pharmacology and Physiology*, **1995**, 22, 851-4	3	16
63	Plasma protein binding of the experimental antitumour agent acridine-4-carboxamide in man, dog, rat and rabbit. *Journal of Pharmacy and Pharmacology*, **1994**, 46, 63-7	4.8	12
62	Effects of phenytoin on cognitive-motor performance in children as a function of drug concentration, seizure type, and time of medication. *Epilepsia*, **1994**, 35, 172-80	6.4	27
61	Rat hepatocyte-mediated metabolism of the experimental anti-tumour agent N-[2Ŧ(dimethylamino)ethyl]acridine-4-carboxamide. *Xenobiotica*, **1993**, 23, 361-71	2	7
60	Maintenance of liver-specific function in cultured hepatocytes in different media. *Biochemical Society Transactions*, **1993**, 21, 70S	5.1	1
59	Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse. *Cancer Chemotherapy and Pharmacology*, **1993**, 32, 320-2	3.5	7
58	Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans. *Cancer Chemotherapy and Pharmacology*, **1993**, 32, 323-5	3.5	13
57	Blood-brain glucose transfer in the mouse. *Neurochemical Research*, **1993**, 18, 591-7	4.6	9
56	Metabolism of the experimental antitumor agent acridine carboxamide in the mouse. *Drug Metabolism and Disposition*, **1993**, 21, 530-6	4	4
55	Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse. *Xenobiotica*, **1992**, 22, 657-69	2	10
54	Blood-brain barrier penetration of felbamate. *Epilepsia*, **1992**, 33, 944-54	6.4	33
53	Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs. *Cancer Chemotherapy and Pharmacology*, **1992**, 29, 439-44	3.5	28
52	Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse. *Cancer Chemotherapy and Pharmacology*, **1992**, 29, 379-84	3.5	24

51	Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose. *Cancer Chemotherapy and Pharmacology*, **1992**, 31, 32-6	3.5	15
50	Cytosol mediated metabolism of the experimental antitumor agent acridine carboxamide to the 9-acridone derivative. *Biochemical Pharmacology*, **1991**, 42, 1879-84	6	27
49	Effects of carbamazepine on psychomotor performance in children as a function of drug concentration, seizure type, and time of medication. *Epilepsia*, **1990**, 31, 51-60	6.4	73
48	Quantitation of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in plasma by high-performance liquid chromatography. *Biomedical Applications*, **1990**, 528, 385-94		7
47	Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. *Cancer Research*, **1990**, 50, 503-8	10.1	18
46	Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. *Cancer Research*, **1990**, 50, 2692-7	10.1	42
45	The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit. *Cancer Chemotherapy and Pharmacology*, **1989**, 23, 291-5	3.5	2
44	The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial. *Cancer Chemotherapy and Pharmacology*, **1988**, 22, 235-40	3.5	3
43	Involvement of glutathione in the metabolism of the anilinoacridine antitumour agents CI-921 and amsacrine. *Drug Metabolism and Drug Interactions*, **1988**, 6, 371-81		9
42	Thiolytic cleavage and binding of the antitumour agent CI-921 in blood. *Drug Metabolism and Drug Interactions*, **1988**, 6, 327-36		4
41	Phase I trial of the amsacrine analogue 9-[(2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921). *Cancer Research*, **1988**, 48, 6593-6	10.1	21
40	Effect of sodium valproate on psychomotor performance in children as a function of dose, fluctuations in concentration, and diagnosis. *Epilepsia*, **1987**, 28, 115-24	6.4	63
39	Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits. *Cancer Chemotherapy and Pharmacology*, **1987**, 20, 13-5	3.5	3
38	The binding of amsacrine to human plasma proteins. *Journal of Pharmacy and Pharmacology*, **1986**, 38, 432-8	4.8	22
37	The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits. *Journal of Pharmacy and Pharmacology*, **1986**, 38, 837-40	4.8	4
36	The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit. *Cancer Chemotherapy and Pharmacology*, **1986**, 18, 208-12	3.5	1
35	Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits. *Cancer Chemotherapy and Pharmacology*, **1986**, 16, 253-6	3.5	10
34	Plasma and biliary disposition of pirenzepine in man. *Clinical and Experimental Pharmacology and Physiology*, **1986**, 13, 241-8	3	2

33	Sustained release of a corticosteroid using polymeric implants. *Agents and Actions*, **1986**, 19, 233-43		1
32	Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. *Cancer Chemotherapy and Pharmacology*, **1985**, 14, 21-5	3.5	16
31	Determination of N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4 -acridinecarboxamide in plasma by high-performance liquid chromatography. *Biomedical Applications*, **1985**, 342, 431-5		14
30	Elimination kinetics of amsacrine in the rabbit: evidence of nonlinearity. *Pharmacology*, **1985**, 31, 50-6	2.3	6
29	Alpha 1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness. *British Journal of Clinical Pharmacology*, **1984**, 18, 806-10	3.8	46
28	Interaction of probenecid with the protein binding of methotrexate. *Pharmacology*, **1984**, 28, 86-9	2.3	19
27	Radioimmunoassay of Methotrexate **1984**, 251-258		
26	Determination of the Anti-Cancer Drug Amsacrine in Biological Fluids by HPLC **1984**, 201-209		
25	Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine. *European Journal of Clinical Pharmacology*, **1983**, 25, 353-6	2.8	15
24	High-performance liquid-chromatographic method for the determination of 4Ŧ(9-acridinylamino)methanesulfon-m-anisidide in plasma. *Biomedical Applications*, **1983**, 276, 367-74		20
23	Propranolol binding in serum: comparison of methods and investigation of effects of drug concentration, pH, and temperature. *Journal of Pharmacological Methods*, **1983**, 10, 1-11		20
22	Fluctuations in salivary carbamazepine and carbamazepine-10,11-epoxide concentrations during the day in epileptic children. *Epilepsia*, **1983**, 24, 716-24	6.4	15
21	Absence of effect of propoxyphene on antipyrine kinetics in the rabbit. *Pharmacology*, **1983**, 27, 241-4	2.3	2
20	Alpha 1 -acid glycoprotein and binding of basic drugs. *Methods and Findings in Experimental and Clinical Pharmacology*, **1983**, 5, 635-48		44
19	Carbamazepine determination in saliva of children: enzyme immunoassay (EMIT) versus high pressure liquid chromatography. *Epilepsia*, **1982**, 23, 185-9	6.4	9
18	The protein binding and elimination of methotrexate after intravenous infusions in cancer patients. *Clinical and Experimental Pharmacology and Physiology*, **1982**, 9, 225-34	3	13
17	Protein binding of methotrexate in sera from normal human beings: effect of drug concentration, pH, temperature, and storage. *Journal of Pharmacological Methods*, **1981**, 5, 203-13		44
16	Use of whole saliva for bioavailability studies with reference to phenytoin. *Journal of Pharmacy and Pharmacology*, **1980**, 32, 586-8	4.8	6

15	Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum. *Clinical Pharmacology and Therapeutics*, **1980**, 28, 695-702	6.1	34
14	Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects. *Clinical Pharmacology and Therapeutics*, **1980**, 27, 170-8	6.1	36
13	Enzyme immunoassay of carbamazepine in serum and saliva. *Journal of Pharmacological Methods*, **1980**, 3, 289-96		4
12	Aberrantly high phenytoin concentrations in saliva. Precaution in monitoring phenytoin concentrations in whole saliva. *British Journal of Clinical Pharmacology*, **1979**, 8, 508-9	3.8	7
11	The effect of label affinity on the sensitivity and specificity of a hapten radioimmunoassay: a comparison of three [125I]diphenylhydantoin radioligands with the 14C-labelled drug. *Journal of Immunological Methods*, **1979**, 27, 363-71	2.5	3
10	The evaluation of a radioimmunoassay for phenothiazines and thioxanthenes using an iodinated tracer. *Journal of Immunological Methods*, **1979**, 31, 159-66	2.5	8
9	High-dose methotrexate therapy--an area of uncertainty. *Australian and New Zealand Journal of Medicine*, **1979**, 9, 722-32		9
8	Interference of 4-amino-4-deoxy-N10-methylpteroic acid with the radioimmunoassay of methotrexate.. *Clinical Chemistry*, **1979**, 25, 491-492	5.5	4
7	An indication of possible impending toxicity during moderately high dose methotrexate infusions. *British Journal of Clinical Pharmacology*, **1978**, 6, 551-2	3.8	3
6	Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay. *British Journal of Clinical Pharmacology*, **1977**, 4, 185-91	3.8	28
5	A rapid, sensitive and specific radioimmunoassay for methotrexate. *Clinica Chimica Acta*, **1977**, 80, 563-72	6.2	25
4	The evaluation of a radioimmunoassay for diphenylhydantoin using an iodinated tracer. *Clinica Chimica Acta*, **1977**, 79, 81-92	6.2	11
3	Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations. *European Journal of Clinical Pharmacology*, **1977**, 11, 71-4	2.8	20
2	Production and characterisation of antisera to diphenylhydantoin suitable for radioimmunoassay. *Journal of Immunological Methods*, **1976**, 10, 317-27	2.5	32
1	Conformational and chemical requirements for antibody recognition of diphenylhydantoin derivatives. *Immunochemistry*, **1976**, 13, 891-4		8